A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma

By Alexander C. Huang, R. Orlowski, Xiaowei Xu, R. Mick, Sangeeth M. George, P. Yan, Sasikanth Manne, A. Kraya, B. Wubbenhorst, Liza Dorfman and 27 more. Nature Medicine, 2019

613 citations recorded by the source corpus.

Immunologic responses to anti-PD-1 therapy in melanoma patients occur rapidly with pharmacodynamic T cell responses detectable in blood by 3 weeks. It is unclear, however, whether these early blood-based observations translate to the tumor microenvironment. We conducted a study of neoadjuvant/adjuvant anti-PD-1 therapy in stage III/IV melanoma. We hypothesized that immune reinvigoration in the tumor would be detectable at 3 weeks and that this response would correlate with disease-free survival. We identified a rapid and potent anti-tumor response, with 8 of 27 patients experiencing a complete or major pathological response after a single dose of anti-PD-1, all of whom remain disease free. These rapid pathologic and clinical responses were associated with accumulation of exhausted CD8 T cells in the tumor at 3 weeks, with reinvigoration in the blood observed as early as 1 week. Transcriptional analysis demonstrated a pretreatment immune signature (neoadjuvant response signature) that was associated with clinical benefit. In contrast, patients with disease recurrence displayed mechanisms of resistance including immune suppression, mutational escape, and/or tumor evolution. Neoadjuvant anti-PD-1 treatment is effective in high-risk resectable stage III/IV melanoma. Pathological response and immunological analyses after a single neoadjuvant dose can be used to predict clinical outcome and to dissect underlying mechanisms in checkpoint blockade. Neoadjuvant PD-1 blockade in patients with resectable melanoma followed by adjuvant maintenance results in early immunological effects driving clinical benefit and reveals transcriptional and genomic mechanisms of response.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/602590a44ea39fca8907535f396fb7b76cd31a14

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Neoadjuvant checkpoint blockade for cancer immunotherapy (2020, methodology): “using pembrolizumab (anti–PD-1) monotherapy for only 3 weeks preoperatively showed a lower rate of side effects but also a lower response rate (51).”
Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms (2020, methodology): “(Huang et al., 2019) Samples were collected either before or 3 weeks after treatment with a single flat dose of pembrolizumab 200mg intravenously.”
Regulatory mechanisms of PD-1/PD-L1 in cancers (2024, background): “Currently, PD-1 blockade therapy has been applied in the immunotherapy of various advanced cancers including melanoma [168], non-small cell lung cancer [169], and colorectal cancer [170].”